Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct-Reference-Cited by-同舟云学术

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

Published:2003-05 Issue:5 Volume:17 Page:900-909
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Löffler A,Gruen M,Wuchter C,Schriever F,Kufer P,Dreier T,Hanakam F,Baeuerle P A,Bommert K,Karawajew L,Dörken B,Bargou R C

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2402890.pdf

Reference59 articles.

1. Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1999. CA: Cancer J Clin 1999; 49: 8–31, 31.

2. Österborg A, Fassas AS, Anagnostopoulos A, Dyer MJS . Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukemia. Br J Haematol 1996; 93: 151–153.

3. Österborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574.

4. Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clo V et al. Treatment of B-cell non-Hodgkin's lymphoma with anti-CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol 2001; 37: 13–25.

5. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195.

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation;Science Advances;2024-09-06

2. Current Trends and Innovative Approaches in Cancer Immunotherapy;AAPS PharmSciTech;2024-07-24

3. T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies;Cancers;2024-04-20

4. A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023;Heliyon;2024-01

5. Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation;International Journal of Molecular Sciences;2023-11-09